NEW YORK, June 16 - Europroteome of Hennigsdorf, Germany, has signed a research collaboration with a consortium of German academic centers to develop proteomics-based diagnostics for breast cancer, the company said today.
Europroteome will analyze protein expression patterns for several hundred serum samples of breast cancer patients provided by GENICA (the Interdisciplinary Study Group on Gene Environment Interaction and Breast Cancer in Germany), a national scientific network of cancer researchers in Germany.
The goal of the collaborative project is to develop novel non-invasive and blood-based screening tests to identify early-stage breast cancer.
Europroteome will correlate protein expression patterns in the serum samples with medical outcome data. The company said it recently conducted a similar study with the University of Magdeburg to use protein patterns for the identification of patients in early stages of stomach and colon cancer.
The first results from the GENICA project are expected over the next couple of months, Europroteome said.